Abstract
BackgroundEmerging evidence reveals that microRNAs (miRNAs) play a crucial role in tumor progression, but the underlying mechanism of microRNAs in lung squamous cell cancer (LSCC) remains unclear.MethodWestern-blotting and quantitative real-time PCR (q-PCR) were carried out to detect mRNA and protein expression. Cell proliferation was evaluated by Cell Counting Kit-8 (CCK-8), colony-forming assay or sphere-forming assay, respectively.ResultsMiR-214-3p was markedly de-regulated in LSCC tissues and was inversely related to the level of Yes-associated protein1 (YAP1), which is the core transcription regulator of the Hippo signaling pathway. Kaplan–Meier survival curves illustrated that patients with high miR-214-3p expression demonstrated more favorable clinical outcomes. MiR-214-3p overexpression (OE) repressed proliferation and cancer stem-like cells (CSCs) properties in vitro and in vivo xenograft mouse model. Mechanistically, luciferase activity assay revealed that miR-214-3p directly targets YAP1 by specifically binding on the 3′ UTR of YAP1.ConclusionMiR-214-3p plays a pivotal role in CSCs properties by targeting YAP1, which provides a potential treatment strategy for LSCC patients.
Highlights
Emerging evidence reveals that microRNAs play a crucial role in tumor progression, but the underlying mechanism of microRNAs in lung squamous cell cancer (LSCC) remains unclear
We reported that miR-214-3p inhibited cancer stem cells (CSCs) capacity by targeting Yes-associated protein1 (YAP1) in LSCC
MiR‐214‐3p is downregulated in LSCC and is significantly associated with better clinical prognosis While YAP1 is elevated, the miR-214-3p is downregulated in tumor species compared to the matched normal bronchial epithelium using quantitative real-time PCR (q-PCR) analysis [19, 20]
Summary
Emerging evidence reveals that microRNAs (miRNAs) play a crucial role in tumor progression, but the underlying mechanism of microRNAs in lung squamous cell cancer (LSCC) remains unclear. Compared with AC, the mainstream treatment regimens for lung squamous cell cancer (LSCC) are still platinum-containing chemotherapeutics and immune therapy, and the targeted therapy for MicroRNAs are a cluster of noncoding RNAs that modulate gene expression [2]. Increasing evidence has shown that aberrant miRNA expression participates in diverse pathogenic processes, such as tumor apoptosis and CSC properties [3,4,5,6]. MiR-205 OE remarkably decreases the proliferation of CSCs in human pancreatic cancer [10] while low expression of miR-613 contributed to the
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
